NCT00152451已完成2 期
An Open-label, Exploratory, Multicenter, Dose-escalation Study Examining the Efficacy, Safety and Tolerability of Ucb 44212 Used at Doses of 10 mg, 20 mg, 40 mg and 80 mg b.i.d. (Total Daily Dose of 20 to 160 mg) in Adult Subjects (18-65 Years) With Refractory Epilepsy Suffering From Partial Onset Seizures (Whether or Not Secondarily Generalized) and Treated With 1, 2 or 3 Approved Antiepileptic Drugs
UCB S.A. - Pharma Sector7 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2005年5月19日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 31
- 试验地点
- 7
- 主要终点
- Percentage Change From Baseline in Seizure Frequency Per Week of Partial Onset Seizures (Type I) During the Up-titration Period
研究概览
简要总结
This trial will evaluate the efficacy and safety of ucb 44212 as add on therapy in subjects with focal epilepsy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males/Females from 18 to 65 years of age (minimum body weight of 40 kg)
- •Subjects with a confirmed diagnosis of epilepsy suffering from partial onset seizures whether or not secondarily generalized
- •Subjects who have been treated for epilepsy for >=6 months and are currently uncontrolled while being treated with 1-3 concomitant Antiepileptic Drug (AEDs)
- •Female subjects without childbearing potential; Female subjects with childbearing potential are eligible if they use a medically accepted non-hormonal contraceptive method
排除标准
- •Seizures occurring in clusters.
- •Status epilepticus within 6 months of Visit 1
- •History of non-epileptic seizures
- •Subjects on vigabatrin
- •Subjects on felbamate, unless treatment has been continuous for >2 years
- •Ongoing psychiatric disease other than mild controlled disorders.
- •Subjects with clinically significant organ dysfunction
- •Known allergic reaction or intolerance to pyrrolidine derivatives and/or excipients
- •Pregnant or lactating women
- •Subjects currently taking levetiracetam (LEV)
- •Use of benzodiazepines (for any indication) taken at a higher frequency than an average of once a week, unless counted as one of the concomitant Antiepileptic Drug (AEDs)
研究组 & 干预措施
Seletracetam
Experimental
Escalating doses twice daily were to be administered.
干预措施: Seletracetam (ucb 44212) (Drug)
结局指标
主要结局
Percentage Change From Baseline in Seizure Frequency Per Week of Partial Onset Seizures (Type I) During the Up-titration Period
时间窗: During the Up-titration Period (Week 5 to Week 12), compared to Baseline Period (Week 1 to Week 4)
Calculated as (7-day seizure frequency during the up-titration period) - (7-day seizure frequency during the Baseline Period (Week 1 to Week 4)), divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial onset seizure frequency from Baseline. The duration of the Up-Titration Period was 8 weeks (Visit 3/Week 5 to Visit 7/Week 12).
次要结局
- Percentage Change From Baseline in Seizure Frequency Per Week for All Seizure Types (Types I+II+III) Overall in the Up-titration Period(During the Up-Titration Period (Week 5 to Week 12), compared to Baseline Period (Week 1 to Week 4))
- Seizure Frequency Per Week for Partial Onset Seizure (Type I) Overall in the Up-titration Period(During the Up-Titration Period (Week 5 to Week 12))
- Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) Overall in the Down-titration Period(During the Down-Titration Period (Week 13 to Week 15), compared to Baseline Period (Week 1 to Week 4))
- Change From Baseline in Seizure Frequency Per Week for All Seizure Types (Types I + II + III) Overall in the Down-titration Period(Week 13 to Week 15, compared to Baseline Period (Week 1 to Week 4))
- Percentage Change From Baseline in Seizure Frequency Per Week of Partial Onset Seizures (Type I) by Visit Over the Treatment Period (Up-titration + Down-titration)(During the Treatment Period (Week 5 to Week 15), compared to Baseline Period (Week 1 to Week 4))
- Seizure Frequency Per Week for Partial Onset Seizure (Type I) Overall in the Down-titration Period(During the Down-Titration Period (Week 13 to Week 15))
- Seizure Frequency Per Week for All Seizure Types (Type I+II+III) by Visit Over the Treatment Period(During the Treatment Period (Week 5 to Week 15))
- Responder Rate in Partial Onset Seizures (Type I) Over the Up-titration Period(Week 12, compared to Baseline Period (Week 1 to Week 4))
- Percentage of Participants With Categorized Response to the Treatment in Partial Onset Seizures (Type I) Over the Up-titration Period(Week 12, compared to Baseline Period (Week 1 to Week 4))
- Percentage Change From Baseline in Seizure-free Days Per Week Over the Up-titration Period(Week 5 to Week 12, compared to Baseline Period (Week 1 to Week 4))
- Change From Baseline in Seizure Frequency Per Week for All Seizure Types (Types I+II +III) Overall in the Up-titration Period(Week 5 to Week 12, compared to Baseline Period (Week 1 to Week 4))
- Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) by Visit Over the Treatment Period (Up-titration + Down-titration)(Week 5 to Week 15, compared to Baseline Period (Week 1 to Week 4))
- Percentage Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) Overall in the Down-titration Period(During the Down-Titration Period (Week 13 to Week 15), compared to Baseline Period (Week 1 to Week 4))
- Seizure Frequency Per Week for Partial Onset Seizures (Type I) by Visit Over the Treatment Period(During the Treatment Period (Week 5 to Week 15))
- Seizure Frequency Per Week for Partial Onset Seizure (Type I) Overall in the Treatment Period(During the Treatment Period (Week 5 to Week 15))
- Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) During the Up-titration Period(Week 5 to Week 12, compared to Baseline Period (Week 1 to Week 4))
- Percentage Change From Baseline in Seizure Frequency Per Week for All Seizure Types (Types I+II+III) by Visit Over the Treatment Period (Up-titration + Down-titration)(During the Treatment Period (Week 5 to Week 15), compared to Baseline Period (Week 1 to Week 4))
- Percentage Change From Baseline in Seizure Frequency Per Week for All Seizure Types (Types I+II+III) Overall in the Down-titration Period(During the Down-Titration Period (Week 13 to Week 15), compared to Baseline Period (Week 1 to Week 4))
- Seizure Frequency Per Week for All Seizure Types (Type I+II+III) Overall in the Treatment Period(During the Treatment Period (Week 5 to Week 15))
- Seizure Frequency Per Week for All Seizure Types (Type I+II+III) Overall in the Up-titration Period(During the Up-Titration Period (Week 5 to Week 12))
- Seizure Frequency Per Week for All Seizure Types (Type I+II+III) Overall in the Down-titration Period(During the Down-Titration Period (Week 13 to Week 15))
- Change From Baseline in Seizure Frequency Per Week for All Seizure Types (Types I+II+III) by Visit Over the Treatment Period (Up-titration + Down-titration)(Week 5 to Week 15, compared to Baseline Period (Week 1 to Week 4))
研究者
研究点 (7)
Loading locations...
相似试验
已完成
2 期
Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking LevetiracetamEpilepsy, PartialNCT00152503UCB Pharma SA59
已完成
2 期
A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal EpilepsyHighly Drug-resistant Focal EpilepsyNCT02495844UCB Biopharma S.P.R.L.55
已完成
1 期
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB0942 in Healthy Japanese and Caucasian SubjectsHealthy Japanese and Caucasian SubjectsNCT03168984UCB Biopharma S.P.R.L.48
终止
2 期
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)Cognitive Impairment Associated With Schizophrenia (CIAS)NCT02855411Biogen35
尚未招募
2 期
The Efficacy and Safety of The Fuzuloparib Combination With BevacizumabRecurrent Ovarian CancerNCT05819060Fudan University44